PCC

Beyond's analysis on PCC

• 2026-08-06 — Insilico Medicine advances AI-driven drug discovery with ISM9077, a potential first-in-class 'pipeline-in-a-drug' candidate targeting aging and ocular diseases

Recent news mentioning PCC

• 2026-09-04 — TEADIT Hosts PCC-1 Course with Record Attendance
• 2026-08-20 — Founder Group Secures $1.5 Million Solar EPCC Subcontract for 29.99MW Malaysia Project
• 2026-08-19 — Luma and PCC Partner to Bring Patient-Centered, AI-Enabled Communications to 300+ Pediatric Practices
• 2026-08-12 — Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
• 2026-08-06 — AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
• 2026-08-03 — INTEGRITY COMMUNITY BUILDERS AND PCCP ANNOUNCE PROGRAMMATIC VENTURE

Browse the full archive →